MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Lumbar Punctures in Parkinson’s Research

    A. Navangul, H. Matthews, M. Bartlett, H. Groves, S. Stott, A. Noyce (London, United Kingdom)

    Objective: This study aims to explore patient perspectives on lumbar punctures for cerebrospinal fluid (CSF) analysis in Parkinson’s disease (PD) research, with the objective of…
  • 2024 International Congress

    Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study

    S. Markova, M. Baladi, M. Lee, C. Chen (Palo Alto, USA)

    Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…
  • 2024 International Congress

    SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update

    K. Meilleur, K. Seppi, F. Krismer, R. Simoes, T. Lampreia, J. Corvol, S. Sambin, G. Hoglinger, C. Schindler, A. Schnitzler, C. Hartmann, K. Eggert, H. Pape, A. Ludolph, J. Kassubek, O. Rascol, M. Rumbel, D. Schulz, S. Darrow, Y. Deng, P. Gupta, S. Stanton, J. Esteban, H. Zhao, M. Yarborough, R. Fong (Carlsbad, USA)

    Objective: To provide an update on the baseline demographics and safety from the HORIZON Clinical Trial of ION464 Background: Multiple System Atrophy (MSA) is a…
  • 2024 International Congress

    Coordinated Reset Vibrotactile Therapy for the Treatment of Bradykinesia in Parkinson’s Disease Patients

    P. Luu, E. Kabasenche, M. Gutierrez, M. Fisher, B. Gaston, R. Shusterman, K. Morgan, D. Tucker (Eugene, USA)

    Objective: The present research examines a novel non-invasive vibrotactile device for stimulation of fingertips in a pattern that aims to disrupt pathological physiological beta-band oscillations…
  • 2024 International Congress

    Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease

    J. Ferreira, J. Lee, H. Ma, B. Jeon, W. Poewe, A. Antonini, F. Stocchi, D. Rodrigues, M. Fonesca, J. Rocha, G. Castilla-Fernández, J. Holenz, O. Rascol (Lisbon, Portugal)

    Objective: The Korean and European ADOPTION studies aimed to explore the efficacy of opicapone (OPC) 50 mg versus an additional 100 mg levodopa dose to…
  • 2024 International Congress

    AccessPD Registry Update: Accelerating Parkinson’s Disease Research Through Integrated Digital Solutions

    Y-H. Chang, M. Periñan, A. Noyce (London, United Kingdom)

    Objective: To update on AccessPD's progress, emphasising the growth in patient recruitment, data integration, and the preliminary analysis aimed at advancing Parkinson's disease (PD) research.…
  • 2024 International Congress

    A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler

    T. van Laar, F. Grasmeijer, M. Hoppentocht (Groningen, Netherlands)

    Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…
  • 2024 International Congress

    Estimating the Proportion of Parkinson’s Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year

    M. Pang, J. Edgerton, L. Zhu, S. Belachew, D. Taylor, C. Kanzler, M. Yang, F. Nahab, C. Shen (Cambridge, USA)

    Objective: To determine what percentage of subjects with early Parkinson’s disease demonstrated no measurable worsening of MDS-UPDRS motor scores over 52 weeks in a Phase…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

    R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)

    Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…
  • « Previous Page
  • 1
  • …
  • 172
  • 173
  • 174
  • 175
  • 176
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley